Trial Recruitment Closes On Novo’s Next Big Semaglutide Bet: Alzheimer’s Disease
Twin EVOKE Studies Aim To Prove Neurological Benefits
Semaglutide has become a game-changer in type 2 diabetes and overweight patients, but Novo Nordisk is hoping to prove it can also slow cognitive decline in Alzheimer’s disease. It’s a long shot, but two large Phase III studies are now well underway to show just that.
